A Phase 2/3 interventional study of IPN60340 + azacitidine + venetoclax and Placebo + azacitidine + venetoclax in Acute Myeloid Leukaemia (AML) and Acute Myeloid Leukaemia, sponsored by Ipsen. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Ipsen · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to find out how well the study drug IPN60340 works to treat participants with acute myeloid leukemia. Acute myeloid leukemia is a rare blood cancer that grows quickly. This study's main aim is to compare the percentage of participants who reach complete remission within the first 6 months of treatment between the 2 study arms (study drug and standard medicines compared to placebo and standard medicines).
In this study all participants will receive azacitidine and venetoclax plus either the study drug IPN60340 or placebo. Venetoclax will be given as a tablet by mouth once each day in 28-day cycles. Azacitidine will be given by injection under the skin (subcutaneously) or through the veins (intravenously) daily for the first 7 days of each 28-day cycle. IPN60340 or placebo (depending on which arm of the study the participant is assigned to) will be given through the veins (intravenously) on day 1 of each 28-day cycle.
There will be 4 periods in this study:
Participants will undergo blood sampling, urine collections, physical examinations, clinical evaluations, electrocardiograms (ECG: recording of the electrical activity of heart), bone marrow aspirates (sampling of the liquid part of the bone marrow). Some participants will also undergo pregnancy testing. Participants in the Phase 3 portion of the study will also be asked to fill in questionnaires.
The time each participant will be in this study will vary based on how well the medicine works to treat the participant's AML. Azacitidine and venetoclax plus either IPN60340 or placebo will be provided to participants who tolerate it for as long as their disease does not progress. Participants may withdraw consent to participate at any time.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
This study's planned enrollment of 540 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Browse Leukemia, Myeloid, Acute studies →Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Current diagnosis of:
I. Acute promyelocytic leukemia (APL) II. Active or uncontrolled central nervous system (CNS) leukemia III. Any γ9δ2TC neoplasm
Presence of surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to randomization.
NOTE: Participants with known positive HBsAb may be randomized provided they are hepatitis B-vaccinated and have negative HBsAg and HBcAb.
Positive antibody test result at screening or within 3 months of randomization unless HCV-RNA negative test is documented.
NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled if a confirmatory negative hepatitis C ribonucleic acid (RNA) test is obtained.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In phase 2b, approximately 90 participants will be randomized in a 1:1 ratio to IAV. In phase 3, approximately 450 participants will be randomized in a 1:1 ratio to IAV. Regardless of the phase, participants will be randomized prior to dosing. Participants who are enrolled in phase 2b of the study will not be allowed to enroll in phase 3 of the study.
Biological: IPN60340 + azacitidine + venetoclax
In phase 2b, approximately 90 participants will be randomized in a 1:1 ratio to PAV. In phase 3, approximately 450 participants will be randomized in a 1:1 ratio to PAV. Regardless of the phase, participants will be randomized prior to dosing. Participants who are enrolled in phase 2b of the study will not be allowed to enroll in phase 3 of the study.
Drug: Placebo + azacitidine + venetoclax
Drug page: Anti-BTN3A Agonistic Monoclonal Antibody ICT01
: IPN60340 + azacitidine + venetoclax Participants will receive: * IPN60340 per protocol by intravenous (IV) infusion in each 28-day treatment cycle * azacitidine by subcutaneous (SC) or IV daily for the first week in each 28-day treatment cycle * venetoclax orally daily every day of each 28-day treatment cycle
Also known as: ICT01
Drug page: Sodium Chloride
Participants will receive: * Placebo per protocol by intravenous (IV) infusion in each 28-day treatment cycle * azacitidine by subcutaneous (SC) or IV daily for the first week in each 28-day treatment cycle * venetoclax orally daily every day of each 28-day treatment cycle
Also known as: NaCl
(Phase 2b and Phase 3) Percentage of participants with Complete Remission (CR)
Complete remission (CR) as defined according to ELN 2022 criteria
Time frame: From randomization to end of Cycle 6 (approximately 6 months)
(Phase 2b) Overall Survival (OS)
Defined as time from randomization to the date of death from any cause
Time frame: From randomization until end of study (up to approximately 6 years)
(Phase 2b) Duration of Complete Remission (DoCR)
Defined as time from achievement of CR to hematological relapse or death from any cause, whichever occurs first
Time frame: From first documented CR until end of study (up to approximately 6 years)
(Phase 2b) Event-Free Survival (EFS)
Defined as time from randomization to the date of induction treatment failure (ITF), relapse from complete remission (CR), or death from any cause, whichever occurs first.
Time frame: From randomization to end of study (up to 6 years)
(Phase 2b) Composite Complete Remission Rate (CRc)
Composite complete remission (CRc), defined as the composite of complete remission (CR), complete remission with partial hematologic recovery (CRh), and complete remission with incomplete hematologic recovery (CRi), according to ELN 2022 criteria
Time frame: From randomization to end of Cycle 6 (approximately 6 months)
(Phase 2b) Complete Remission with Minimal Residual Disease Negative (CR MRD-negative)
Complete remission with minimal residual disease negativity (CR MRD-negative) according to ELN criteria
Time frame: From randomization to end of cycle 6 (6 months)
(Phase 2b) Composite Complete Remission with MRD Negative (CRc MRD-negative)
Composite complete remission (CRc), defined as CR, CRh, and CRi, with minimal residual disease (MRD) negativity according to ELN 2022 criteria
Time frame: From randomization to end of Cycle 6 (approximately 6 months)
(Phase 2b) Transfusion Independence (TI) Conversion Rate
Transfusion independence (TI) conversion rate, defined as a ≥56-day period without red blood cell (RBC) or platelet transfusion after start of treatment in participants requiring transfusion within 28 days prior to the first dose of study treatment.
Time frame: From randomization until end of study (up to approximately 6 years)
(Phase 2b) Percentage of participants with Treatment-Related Adverse Events (TEAEs)
TEAEs with severity grading according to the NCI CTCAE version 6.0, except the severity of CRS and ICANS which will be graded according to the ASTCT Consensus Grading Criteria, from the first administration of study drug up to 28 days after the last dose.
Time frame: From first administration of study drug up to 28 days after last dose
(Phase 3) Overall Survival (OS)
Overall survival (OS), defined as the time from randomization to death from any cause
Time frame: From randomization until end of study (up to approximately 6 years)
(Phase 3) Duration of Complete Remission (DoCR)
Duration of complete remission (DoCR), defined as the time from achievement of CR to hematological relapse or death from any cause, whichever occurs first
Time frame: From first documented CR until end of study (up to approximately 6 years)
(Phase 3) Event-Free Survival (EFS)
Event-free survival (EFS), defined as the time from randomization to induction treatment failure (ITF), relapse from CR, or death from any cause, whichever occurs first
Time frame: From randomization until end of study (up to approximately 6 years)
(Phase 3) Composite Complete Remission (CRc)
Composite complete remission (CRc), defined as CR, CRh, and CRi according to ELN 2022 criteria
Time frame: From randomization to end of Cycle 6 (approximately 6 months)
(Phase 3) Complete Remission with Minimal Residual Disease Negative (CR MRD-negative)
Complete remission with minimal residual disease negativity (CR MRD-negative) according to ELN criteria
Time frame: From randomization to end of Cycle 6 (approximately 6 months)
(Phase 3) Composite Complete Remission with MRD Negative (CRc MRD-negative)
Composite complete remission (CRc), defined as CR, CRh, and CRi, with MRD negativity
Time frame: From randomization to end of Cycle 6 (approximately 6 months)
(Phase 3) Transfusion Independence (TI) Conversion Rate
Transfusion independence (TI) conversion rate, defined as a ≥56-day period without red blood cell (RBC) or platelet transfusion after start of treatment in participants requiring transfusion prior to study entry
Time frame: From randomization until end of study (up to approximately 6 years)
(Phase 3) Change from baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) global health status, fatigue, and physical functioning subscales
Change from baseline in global health status, fatigue, and physical functioning subscales
Time frame: From baseline until end of study (up to approximately 6 years)
(Phase 3) Percentage of Participants Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Percentage of participants undergoing HSCT in remission following study treatment
Time frame: From baseline until end of study (up to approximately 6 years)
No study locations are listed for this record.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
Data sharing details ↗ · www.ipsen.com
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for May 2031, 54 months later.
Of 31 phase 2/3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 86. This study's planned 54 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anti-BTN3A Agonistic Monoclonal Antibody ICT01